{"filing":{"accession_number":"0001599298-26-000074","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-08-26","report_date":"2026-08-25","primary_document":"smmt-20260825.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000074/smmt-20260825.htm"},"events":[{"id":29662,"run_id":27178,"accession_number":"0001599298-26-000074","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Summit disclosed positive Phase III clinical trial results for its partner Akeso's HARMONi-GI1 study of ivonescimab in advanced biliary tract cancer, achieving statistically significant overall survival superiority versus durvalumab plus chemotherapy. This represents a material operational/clinical milestone for Summit's lead investigational asset (SMT112/ivonescimab), supporting its ongoing regulatory pathway and commercial potential, though the trial was sponsored and conducted by Akeso rather than Summit directly. The event is operational rather than a specific earnings release, regulatory approval, or M\u0026A activity.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-08-26","form":"8-K","submitted_at":null,"items":[{"id":32021,"accession_number":"0001599298-26-000074","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed positive Phase III clinical trial results for its partner Akeso's HARMONi-GI1 study of ivonescimab in advanced biliary tract cancer, achieving statistically significant overall survival superiority versus durvalumab plus chemotherapy. This represents a material operational/clinical milestone for Summit's lead investigational asset (SMT112/ivonescimab), supporting its ongoing regulatory pathway and commercial potential, though the trial was sponsored and conducted by Akeso rather than Summit directly. The event is operational rather than a specific earnings release, regulatory approval, or M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T13:18:43.326095+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":32021,"accession_number":"0001599298-26-000074","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed positive Phase III clinical trial results for its partner Akeso's HARMONi-GI1 study of ivonescimab in advanced biliary tract cancer, achieving statistically significant overall survival superiority versus durvalumab plus chemotherapy. This represents a material operational/clinical milestone for Summit's lead investigational asset (SMT112/ivonescimab), supporting its ongoing regulatory pathway and commercial potential, though the trial was sponsored and conducted by Akeso rather than Summit directly. The event is operational rather than a specific earnings release, regulatory approval, or M\u0026A activity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-26T13:18:43.326095+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-08-26"}]}